FDA action counts
| Total FDA actions | 5 |
|---|---|
| Warning letters | 0 |
| Recalls | 4 |
| Approval records | 1 |
| Form 483 inspection citations | 0 |
| Most recent action | June 24, 2026 |
Enforcement history
On 2026-06-24, Argus HQ recorded a FDA recall for PAI Holdings LLC, rated "high" severity in Argus HQ's classification: PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN AQUEOUS BASE WITH CHERRY FLAVOR, 25 Grams Acti… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for PAI Holdings LLC, rated "high" severity in Argus HQ's classification: PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN AQUEOUS BASE WITH CHERRY FLAVOR, 50 Grams Acti… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for PAI Holdings LLC, rated "high" severity in Argus HQ's classification: PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN SORBITOL BASE WITH CHERRY FLAVOR, 50 Grams Act… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for PAI Holdings LLC, rated "high" severity in Argus HQ's classification: PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN SORBITOL BASE WITH CHERRY FLAVOR, 25 Grams Act… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. In total, PAI Holdings LLC has 4 FDA events on file with Argus HQ across the sources Argus HQ currently tracks (FDA Warning Letters, recalls, drug/biologic approvals, and Form 483 inspection observations).
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. PAI Holdings LLC has 4 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event.
Frequently asked questions
- How many FDA actions has PAI Holdings LLC had?
- Argus HQ has recorded 4 FDA events for PAI Holdings LLC: 0 warning letters, 4 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- What is the most recent FDA action against PAI Holdings LLC?
- The most recent FDA event Argus HQ has on file for PAI Holdings LLC is dated 2026-06-24, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- Does Argus HQ track new FDA actions for PAI Holdings LLC automatically?
- Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to PAI Holdings LLC is observed, this page's event count and history update automatically.
- How many FDA actions does Argus HQ track for PAI Holdings LLC?
- 5 total: 0 warning letters, 4 recalls, 1 approval record, and 0 Form 483 inspection citations.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
- PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN SORBITOL BASE WITH CHERRY FLAVOR, 25 Grams Act… →
- PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN SORBITOL BASE WITH CHERRY FLAVOR, 50 Grams Act… →
- PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN AQUEOUS BASE WITH CHERRY FLAVOR, 50 Grams Acti… →
- PAI Holdings LLC — Class II recall: VistaPharm, KERR INSTA-CHAR IN AN AQUEOUS BASE WITH CHERRY FLAVOR, 25 Grams Acti… →
- PAI HOLDINGS — ANDA approval: PROPRANOLOL HYDROCHLORIDE (unspecified) →
Compare with
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Verified from FDA.gov · Last updated: Jun 24, 2026Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). PAI Holdings LLC's Complete FDA Record. Digital Empire LLC. Retrieved from https://argushq.ai/company/pai-holdings-2
"PAI Holdings LLC's Complete FDA Record." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/pai-holdings-2.
Argus HQ Research. "PAI Holdings LLC's Complete FDA Record." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/company/pai-holdings-2.
@misc{argushq_argushq_ai_company_pai_holdings_2_2026,
title = {PAI Holdings LLC's Complete FDA Record},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/company/pai-holdings-2},
note = {Accessed: July 15, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗